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Introduction
Abstract: The objective of this work is to map the main actors within the Brazilian innovation system framework in the field of tissue engi-
neering and bioprinting, and analyze the main conditioners related to entrepreneurship and innovation. While keeping as a backdrop, the 
history of 3D Biotechnology Solutions startup, its challenges and projects. Tissue engineering is a subcategory of regenerative medicine 
with the purpose of repairing or substituting, partially or completely, tissues or organs that have been affected by some disease or lesion. 
The conventional methods used for the production of these biomaterials via tissue engineering do not have the capacity to mimic the reality 
of native structures in the nano, micro and macro scales, while guaranteeing the reproducibility and scalability of the materials. Technologies 
such as 3D bioprinting or additive manufacturing could change the way that many diseases are treated in the medium term by replacing the 
damaged tissues with custom bio-similar constructs. Mapping and reflections based on the innovation systems framework contribute to 
organize stimulus policies, stimulate interaction between actors, identify gaps and technological demands and periodically organize the 
analysis and expansion of this system in Brazil.
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Introduction
3D bioprinting has emerged as a technological platform with great 
potential to meet the growing demands of regenerative medicine. Tissue 
engineering (TE) as a subcategory within the field of regenerative medicine 
was defined by Langer and Vacanti 1 as a “an interdisciplinary field that 
applies the principles of engineering and life sciences to the development 
of replacements that restore, maintain or improve tissue function”. TE 
develops alternatives to induce a tissue regeneration process, overcoming 
some disadvantages found in organ transplantation, such as the lack of 
donors nd the need for immunosuppressive therapy. TE applications also 
have potential for the conception of in vitro models of healthy or patho-
logical tissues and organs, assisting in drug screening, evaluation of new 
therapies, as well as the investigation of complex phenomena that occur 
within the progression of a disease such as cancer 2.
In addition to their high scientific potential, these models run into 
ethical questions, the issue of using animals for drug testing is a practical 
example of how TE is a disruptive technology platform. In Brazil, as of this 
year (2019), comes into force the Normative Resolution of the National 
Council for the Control of Animal Experimentation (Concea) that obliges 
the mandatory substitution of the original method performed on animals by 
the alternative method for research activities. This resolution, which seeks 
to apply the replacement, reduction and refinement (3Rs) principle in the 
country 3 encourages the research community to recognize the importance 
of well-being for animals used in science, and was also officially endor-
sed by the National Health Surveillance Agency (ANVISA) so that these 
methods could be applied for regulatory purposes. The European Union 
has determined, since 2004, the transfer of tests for toxicity assessment 
to in vitro systems. In 2013, it also banned the import of animal-tested 
cosmetic products (Amendment 2003/15 / EC of Directive 76/768 EEC).
The potential use of bioprinters is high because repair of damaged or 
lost tissue is a worldwide concern, as well as the increase in the rates of 
obesity, diabetes and the elderly population. To give you an idea, Brazil 
today has 20.6 million elderly, a figure that represents 10.8% of the popula-
tion. By 2060, the country is expected to have 58.4 million elderly (Brazilian 
Institute of Geography and Statistics-IBGE). A point to note is that the list 
of patients awaiting some type of transplant in Brazil is around 33,000. Even 
though there is an annual increase in the number of transplants performed, 
the demand for organs has been growing at a higher rate.
Hence, with the growing interest of the medical and pharmaceutical 
communities, the demand for these bioproducts has increased and a wide 
range of bioprinting equipment have been developed within the labs of 
research institutions and also by startups4. Therefore, although the number 
of technologies, design and applications have grown as research advan-
ces to create increasingly complex fabric, a series of scientific technical 
challenges need to be overcome such as equipment precision, aseptic 
conditions, amongst others.
From a market perspective, the BCC Research report5 predicts that 
by 2021 this field will reach US$ 1.8 billion. This growth is estimated at a 
compound annual growth rate of 4.3% from 2016 to 2021. Another report 
from the consultancy Grand View Research 6 estimated the global bioprint 
market at US$ 682 million in 2016 expected to reach US$ 2.6 billion by 2024. 
Growth should be driven by new printing technologies as well as by the 
expansion of new applications within the medical field such as vasculari-
zed tissues, vascular grafts, cartilage, bone, skin and other applications.
From a business strategy perspective it is only natural that companies 
offering products for bioprinting will gradually come to provide bioprinting 
products, given the different business possibilities that open up with this 
technological platform. A representative case is of the American company 
Organovo, founded in 2007 it initially focused in products for bioprinting 
(bioprinters, bioinks, etc.) and today is a leader in the co-development of 
bioprinting products, with patent requests for different therapeutic appli-
cations. It is also natural that important ethical, moral and social questions 
have to be analyzed so that an appropriate regulatory framework can be 
put in practice and make possible for bioprinting products to find their 
way to the market and improve patients’ quality of life, as discussed by Li 7.
In this regard, it is important to highlight that other countries for some 
years now have been working toward providing an adequate regulatory 
environment to foster the development of therapeutic applications with 
cells using TE and bioprinting. The creation of an environment conducive 
to research and development can provide companies and institutions an 
advantage in these countries, demanding a robust strategy so that Bra-
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of vanguard technology. In this sense, mapping actors can support the 
organization of policies and funding mechanisms, stimulate cooperation 
and interaction, identify demands and provide a systemic platform for 
periodically analyzing the evolution of this system.
The article is organized into four items other than this introduction. In 
the next two items, the analysis referential based on the innovation systems 
and the characterization of the Brazilian sectoral system will be analyzed. 
Next, we will present the case of 3D Biotechnology solutions startup, its 
history and projects. Finally, we will present some reflections regarding 
the entrepreneurship in this emerging sector. It is noteworthy to highlight 
right away, that the mapping exercise carried out was not exhaustive and 
should not be complete, and that we encourage the constant addition of 
new actors.
The Innovation Systems Approach to Characterize Leveraging 
of Skills in Research Development and Innovation
Innovation system (IS) models have traditionally been applied on a 
national innovation system (NIS) approach. This approach has also been 
applied to analyze industry sectors and specific enabling of sectoral tech-
nologies. This approach has also been applied to analyze industry sectors 
and sector specific technology capabilities. These approaches share the 
view that the innovative process can best be explained by characterizing 
system components and how they interact. Specifically, its actors, ne-
tworks and institutions, including regulatory norms.
The IS approach makes explicit the importance of systemic interactions 
between various components of an invention, of the research, technical 
change, learning, and innovation. Such interactions have multiple internal 
and external sources of information and knowledge coming from diffe-
rent classes of actors and institutions. These interactions have created 
an informal systemic interdependence in the production systems of the 
respective actors, giving rise to what is now called the “Innovation Sys-
tem”. The central idea of the IS approach is the notion that what appears 
as innovation at the aggregate level is in fact the result of an interactive 
process that involves several actors at the micro level, and that alongside 
market forces many of these interactions are governed by non-market 
institutions. The efficiency of this process observed at the macro level thus 
depends on the behavior of individual actors, in addition to the institutions 
that govern their interaction.
It is no surprise that economists in the institutional tradition of in-
novation studies 8, 9 and scholars of evolutionary theories 10 , became the 
strongest supporters of the notion of innovation systems as this point of 
view refers to a continuous process in which institutions (habits, practices 
and rules) coevolve through learning processes, while playing a central 
role in generating innovation and technological change.
From an analytical perspective, the Sectorial Innovation Systems (SIS) 
11 approach takes a multidimensional and dynamic cut of a given industrial 
sector, composed of the following elements:
(i) its products, (ii) agents, such as companies, universities, financial 
institutions, central and regional governments, (iii) knowledge and lear-
ning systems (group courses and research lines) (iv) interrelationships 
and complementarities of basic technologies, supplies and demands, (v) 
mechanisms of interaction between external and within the sector compa-
nies, involved in both market and non-market processes, (vi) competition 
and selection processes, (vii) institutions, understood as productions 
standards, regulations and the job market. This framework serves as a 
practical tool for the design and implementation of innovation policies.
In this sense, Chaminade and Edquist 12 affirm that the innovation 
policies based on the Innovation Systems perspective aim to solve sys-
temic problems or failures, which are not automatically resolved by private 
actors. The authors highlight some possible systemic failures, such as (i) 
the provisioning of infrastructure and investment failures, (ii) failures in 
the technological paradigm transition (iii) lock-in problems, (iv) failures 
in “hard” and “soft” institutions, (v) networking failures, (vi) learning and 
competency failures and (vii) complementarity failures. In practice, this 
approach allows the analysis of blocking and induction mechanisms and 
to delimit the main functions which this system should provide to develop 
virtuously. Table 1 summarizes induction and blocking mechanisms and 
functions of these systems.
Induction Mechanisms Functions Blocking mechanisms
•	 Governmental R&D Programs
•	 Investments Subsidies
•	 Measures that affect relative 
prices
•	 Public purchase notices
•	 Knowledge creation and 
propagation





•	 Legitimation of new technologies
•	 Development of positive 
externalities
•	 Features of the new technology
•	 Weak institutional power
•	 Lack of customer competence
•	 Weak links within the 
collaboration network
•	 Established Lock-in Technology
•	 Lack of long-term goverment 
vision
Adapted from Jacobsson e Bergek 13
Table 1 - Characteristics of Technological Innovation Systems.
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The sectoral system of innovation in Brazilian Bioprinting and 
tissue engineering
The sectoral system of innovation in the Brazilian field of bioprinting is 
in an emerging phase, that is, innovative applications based on this tech-
nological platform begin to be explored economically. This system is made 
up mostly by: university research groups, research institutes, companies 
and startups. In addition, the regulatory agency ANVISA. The analysis 
performed based on the data available from the group research Directory 
of the Lattes2 platform identified 60 research groups and 71 threads of 
research hosted in 30 universities, 2 hospitals and 3 research institutes.
Search Query:
Date: 07/31/2019
Terms: Bioprinting, Tissue engineering and Biofabrication – Exact search: Group name, research field name, research field keyword
Actors
Universities Federal Center of Technological Education of Minas Gerais Brazilian Agricultural Research Com-
pany
Porto Alegre Clinical Hospital Little Prince Children’s Hospital
Paraíba Federal Institute of Education, Science and Technology Federal Institute of Ceará - Rec-
tory
Pontifical Catholic University of Rio Grande do Sul Brazil University
Araraquara University University of Brasilia University of Pernambuco University of Sao Paulo
State University of Minas Gerais Campinas State University
Paulista State University Julio de Mesquita Filho Federal University of Southern Frontier
Federal University of Campina Grande Federal University of Itajubá
Federal University of Mato Grosso do Sul Federal University of Minas Gerais Federal University of 
Pernambuco Federal University of Santa Catarina Federal University of São Carlos
Federal University of Sao Paulo Federal University of Sergipe Federal University of Viçosa Federal 
University of ABC
Federal University of Espirito Santo Federal University of Piaui Universidade Federal do Rio de 
Janeiro
Universidade Federal do Rio Grande do Sul
Universidade Federal do Vale do São Francisco
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Bioprinting areas of practice
Research 
Institutes
CTI Renato Archer Biofabrication, prosthesis, software applications and systems
IPEN Applications
CNPEM LNBio Organoids
INCT Biofabris Development of biomaterials
Dante Pazzanese Institute Cardiovascular therapeutic applications
The Heart Institute (Incor) Cardiovascular therapeutic applications
Startups InSitu Cellular Therapy (2016), Bioprinting Products: Biocuratives
3D Biotechnlogy Solutions 
(2017),
Products for Bioprinting: equipment and supplies
Bioprinting Products: InVitro Models
BioCellTiss (2017), Bioprinting Products: InVitro Models
BioEdTech (2018), Products for Bioprinting: Low cost equipment and educational 
area
TissueLab (2018), Products for Bioprinting: Bioinks
Bioprint3D (2019), Products for Bioprinting: Low cost equipment
GCell (2019) Spheroids
Companies Embrapa Genetic Resources Bioprinting applications: biomaterials, nanopigments, and appli-
cations in agriculture
Natura Cosmetics InVitro Skin models
AC Camargo Câncer Hospital In Vitro models to fight Cancer
Government 
Agencies
ANVISA Advanced Therapy Regulation
Source: Self Developed
 Table 2 - Main actors of the Sectoral System of Bioprinting Innovation
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Among the main research centers in Brazil we can highlight the pio-
neering work of the Biofabrication Research Group of the Information 
Technology Center CTI Renato Archer, which has been using additive 
manufacturing technologies for the creation of prostheses since 1994. 
Also, the research lines by the Embrapa Nanobiotechnology Laboratory, 
in the development of biomaterials originating from agriculture. Finally, 
the cutting edge research by the National Center for Materials Research 
CNPEM on organoid development, amongst others. Moreover, the essen-
tial role of universities in providing the appropriate environment that allows 
connection with this cutting edge area under different lines of research.
An example of a large Brazilian company that comes to view appli-
cations in the field of bioprinting is Natura Cosmetics. One of its ongoing 
projects aims to develop a dermo skin equivalent from the 3D bioprint 
technique to serve as an in vitro platform for cosmetic product evalua-
tion. Fibroblasts, keratinocytes and melanocytes will be co-cultured on 
layer-by-layer polymeric support, following the trend of alternative in vitro 
models, which serve as an alternative to the use of animals for effectiveness 
and safety for the testing of cosmetics. The arrangement for the execution 
of this project includes leading researcher at startup 3D Biotechnology 
Solutions, Dr. Ana Luiza Millás under the supervision of Prof. Silvya Maria-
-Engler Stucchi, from the School of Pharmaceutical Sciences, University 
of São Paulo / USP. Figure 1 below shows the geographical distribution 
of groups, research lines and startups in Brazil.
Most of the system is located in universities and research institutes 
that are concentrated in the states of São Paulo, Minas Gerais, Rio Grande 
do Sul, Santa Catarina, and Rio de Janeiro. Ingeneral it can be said that all 
startups come from centers of excellence in this field which demonstrates 
the important function of any innovation system that is the dissemination 
of knowledge. The emergence of startups is an indication that resource 
mobilization toward enterprise experimentation is also taking place.
It is also worth noting that the groups as well as lines of research pre-
dominantly have an area of activity classified as “Engineering” followed by 
“Health Sciences” and “Biological Sciences”, as shown in Graph 1 below. 
This indicates the interdisciplinary character of the field as researchers 
are encountering TE and Bioprinting from different disciplines and under 
different approaches and lines of research.
As for induction mechanisms and support for innovation, we did not 
identify any specific support line for the development of the field. The 
available support mechanisms are the same for other technology-based 
and innovation-promoting enterprises; however, an important point to 
highlight is the vital role of the São Paulo State Research Foundation - 
FAPESP, which through its PIPE program funded / funds projects in three 
of the four startups in this state.
From the regulatory point of view, it is worth highlighting the position 
of ANVISA, that approved the Resolution of the Collegiate Board (RDC 
260/2018), which establishes specific criteria for studies with advanced 
therapy products, methods that consist of the use of genetic material 
(genes and cells) in various treatments. This resolution covers different 
application possibilities using stem cells for the field of bioprinting and 
tissue engineering.
Figure 1 - Distribution of groups, research lines and startups in the field of Bioprinting and tissue engineering.
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Characteristics of innovation projects in the field of bioprinting 
from the perspective of a startup: The case of 3D Biotechnology 
Solutions - 3DBS
3DBS – 3D Biotechnology Solutions was established in December 
of 2017, registered with the National Register of Legal Entities (CNPJ): 
29.150.401/0001-00, as the first Brazilian startup working in the field of 
bioprinting. Its shop is located in São Paulo, Brazil. Since its opening, 
it has been developing projects for customizing bioprinting equipment 
and consulting services in the area of tissue engineering. 3DBS’ services 
have been in demand both for the development of equipment as well as 
for its Know How within the field of bioprinting. Since its opening it has 
been developing diverse projects to meet specific demands of startups, 
research institutes and universities. Among these we can mention, In Situ 
Cellular Therapy, IPEN, Embrapa, UNICAMP, INCT Biofabris, UFRGS, UFRJ, 
USP/São Paulo.
In these months of operation, so far it has been observed that the main 
client is either the researcher who develops applications or the professors 
in the educational field. His main need is to supply missing knowledge to 
Graph 1 - Predominant area of research groups.
advance research since the field of bioprinting is extremely interdisciplinary 
and is in its early stages in Brazil. Thus, there is a need/demand for support 
to begin research in the field of bioprinting and personalized and close 
assistance to operationalize the lines of research. In addition, there are dif-
ficulties in importing equipment and resources, both from a price, as well as 
from a logistical and customs barrier. Among the elements that compose 
the value proposition of 3DBS we can highlight: reduction in the cost of 
bioprinting, customization for specific purposes, partnerships for the co-
-development of applications, possibility of printing of different materials 
and association with other technical methods such as electrospinning.
Among the next steps, 3DBS has been developing applications that aim 
to explore bioprinting products, and for this purpose it has been deve-
loping specific projects with the support of the São Paulo State Research 
Support Foundation (FAPESP) and partners such as the Federal School of 
Medicine of São Paulo (UNIFESP), the AC Camargo Cancer Center hospital, 
and the Faculty of Pharmaceutical Sciences of USP/São Paulo. Moving 
forward, we will detail the main aspects of these initiatives.
Figure 2 - 3DBS Bioprinters, models Genesis II and Octopus.
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Ongoing 3DBS Projects and their impacts
Project I: Bioprinting of tubular structures and In Vitro models 
– Partnership with USP and FEM Unicamp – PIPE FAPESP phase 
II program support
Cardiovascular diseases are the leading cause of deaths in deve-
loped countries, particularly those that cause flow obstruction as is the 
case of atherosclerosis14. In addition to atherosclerosis, several vascular 
diseases and pathologies lead to aneurysmal degeneration, congenital 
malformation, vasculitis, and traumatic injuries requiring arterial bypass. 
Bypass or revascularization surgery is a surgical procedure that utilizes 
an autologous vascular graft, such as the patient’s own saphenous vein or 
peripheral artery or an artificial graft15. Even today, the autologous graft is 
the gold standard; however, previous surgeries and medical comorbidities 
may limit the availability of these vessels.
Thus, synthetic vascular grafts play an important role in the treatment 
of these clinical conditions as 30% of patients that require bypass surgery 
do not possess adequate or sufficient autologous blood vessels16.Polye-
thylene terephthalate(PET), Dacron and expanded polytetrafluoroethyle-
ne (ePTFE) are the biomaterials commonly used in vascular prostheses, 
awarding satisfactory results when used to replace or bypass large blood 
vessels. However, due to the blood flow velocity in small caliber vessels, 
the clinical performance of these grafts is inferior17, 18. Although biologically 
inert, synthetic vascular prostheses are also susceptible to infections19.
Due to the poor functional performance of commonly used biomate-
rials, strategies have been developed to reduce the factors that influence 
low permeability rates, namely acute thrombus formation and intimal 
hyperplasia20,21. Endothelialization of the luminal surface of the graft 
using autologous endothelial cells has become a successful procedure 
to improve long-term permeability rate (7 years) in artificial vascular grafts 
22. Studies show the use of autologous cells and genetically modified cells 
loaded in biological or synthetic matrices to construct tubular structures 
and subject them to mechanical and chemical stimuli in an attempt to 
develop a small caliber vascular graft 23, 24. As noted with the increasing 
demand for blood vessels and the problematic of existing therapies, 
tissue engineering as a multi and interdisciplinary discipline establishes 
three essential criteria for blood vessel development: i) to present 
biocompatible components with high tensile strength that provide 
mechanical support; ii) have a biocompatible elastic component that 
provides elastic  reserve  and  prevents  the  formation  of  aneurysms 
(elastin  fibers);  iii)  have  a confluent endothelium that prevents intra-
vascular thrombosis.
To achieve these goals, technologies that were previously used for other 
purposes have been adapted over the past decade to meet the demands 
of regenerative medicine and, specifically, tissue engineering. This is the 
case of 3D bioprinting, an adaptation of conventional 3D and electros-
pinning printing techniques, inherited by the textile industry, to produce 
nano and micro fibers.
The 3D printer used in this project was developed under the Phase I 
PIPE/FAPESP program by 3DBS startup. The equipment has two printer 
heads that allow you to work with two bioinks layer- by-layer in the same 
bioconstruct, as well as a photocuring system (ultraviolet light), HEPA 
filters, a camera for recording images during the bioprinting process and 
a fourth rotary axis with controlled speed and diameters for the generation 
of tubular structures (diameters between 2mm and 12mm) (Figure 3).
During Phase I of the PIPE program, tests were performed to valida-
te the equipment, so we had the collaboration of the researcher Prof. Dr. 
Marcos Akira, from the Faculty of Mechanical Engineering at UNICAMP and 
Prof. Dr. Sang Won Han of the Center for Cellular and Molecular Therapy 
(CTCMOL) at UNIFESP. Bioinks with different compositions and rheological 
properties were tested analyzing printability, filament formation, injecta-
bility, the preservation of three-dimensional geometry after crosslinking 
and biocompatibility (cell viability) (vide Figure 4).
Figure 3 - 3D Bioprinter Model Genesis II from 3DBS startup. It possesses a fourth rotary axis for the generation of tubular structures (vascular grafts). Source: author.
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Figure 4 - On the left, tubular alginate (4%) +gelatin (2%) structures loaded with fibroblasts after 11 days of printing. On the right, tubular alginate (6%) 
structure loaded with fibroblasts. Cell viability is higher when gelatin is incorporated. We tested pure alginate bioink, alginate+gelatin compositions 
and alginate with laponite bioink. Source: author.
Project II: Bioprinting of In vitro tumor models - partnership 
with AC Camargo Cancer Hospital
Despite substantial progress in cancer research over the past century, 
the World Health Organization (WHO) has reported that the incidence of 
cancer worldwide has increased from 12.7 million in 2008 to 14.1 million 
in 2012, and the estimate for the next two decades is that this incidence will 
increase to 25 million, with the greatest impact on low and middle income 
countries26. Applied to oncological investigations, bioprinting allows the 
creation of in vitro three-dimensional structures with cellular complexity 
and heterogeneity similar to that found in an in vivo tumor microenviron-
ment, characteristics that are not observed in conventional two-dimen-
sional models27. One of the mechanisms of cancer biology that can best be 
best understood through the use of three-dimensional bioprinting models 
is metastasis, the leading cause of cancer death worldwide.
Accurate models of human tumors are needed to understand how 
complex stromal tumor interactions contribute to tumor growth, pro-
gression and therapeutic response. Models of genetically modified mice 
and cancer cell xenografts in immunocompromised mice have allowed the 
study of tumors in the presence of a tumor microenvironment, but these 
models are expensive, time consuming, do not include human stroma, 
and can be difficult to manipulate. Several advances have been made for 
in vitro culture methods in attempts to better recapitulate the complex in 
vivo tumor microenvironment28, 29, 30, 31.
Matrix-based models, such as collagen or Matrigel, or scaffold-free 
heterotypic co-culture models, including multicellular tumor spheroids, 
allow the integration of additional cell types into 3D culture.
Highlighting the importance of three-dimensional in vitro models for 
the study of cancer and cell interactions for oncogenesis, three-dimen-
sional systems, when compared to 2D systems, demonstrated significant 
changes in the genic expression, proliferation, and tumorigenic phenotype 
profiles32, 33, 34. 3D bioprinting has been used in a variety of approaches 
in an attempt to generate cancer models that simulate spatially defined 
microenvironments34, 35. The spatial orientation of cells within bioprinted 
tissues allows the investigation of tumorigenic phenotypes, such as cell 
migration, as well as the analysis of spatial heterogeneity. Together, these 
results suggest that bioprinted tissues may be useful for drug response 
studies and analysis of cytostatic versus toxic effects of therapies.
In practice the use of 3D models for cancer drug testing will promote a 
faster transfer of basic knowledge to the clinic, increase the effectiveness 
of treatments and lower the costs of drug development as effectiveness 
tests become more accessible. In addition, it will allow the development of 
new experimental protocols for the study of tumor biology, especially the 
mechanisms of metastasis.
Conclusions
The sectoral innovation system of TE and bioprinting has a solid foun-
dation within the academic circle, represented by consolidated groups and 
lines of research in different universities. The system is starting to present 
signs of commercial exploration of different application and correlate areas, 
among these, the supply of equipment and resources for bioprinting, 
consulting and specific training. The regulatory framework has also been 
established and implemented by ANVISA based on the regulatory expe-
riences of other countries.
In general, it is worth mentioning that the field of bioprinting is 
incipient in the world, with the main commercial players beginning 
to consolidate in the last decade. What has been seen is a consistent 
expansion of mainly the number of startups emerging in the market within 
the last couple of years. From a perspective of actions to leverage the 
expansion of this system, the fact that it is an emerging market provides 
a wide range of opportunities to formulate strategies for the promotion of 
Leapfrogging, that is, the notion that areas with less developed technology 
or economic foundations can advance rapidly through the adoption of 
specific mechanisms of support without having to go through intermediate 
steps.
In this sense, to promote the interaction of actors with each other 
and with investors is an important induction mechanism, both to promote 
the contact between different related areas of knowledge, as well as to 
provide long-term financing. Having access to long-term financing is vital 
especially for developing applications that require clinical testing. Thus, 
reducing the entrepreneur’s risk by providing access to public or priva-
te resources can stimulate the development of new startups by fostering 
bench-to-market movement. On the other hand, to stimulate the demand 
for applications through specific public bidding can be an interesting re-
source because it allows entrance in the market of innovative applications 
in the health field in a controlled manner. In addition, it legitimizes new 
technologies by supporting the initial formation of this market.
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